2014-02-03 17:32:46 - David Wishart, Professor of Computing Science & Biological Sciences at the University of Alberta will give a keynote presentation on “Quantitative Metabolomics and Medical Biomarkers: Challenges and Opportunities” at the Inaugural Metabolomics Conference - Advances & Applications in Human Disease to be held in Cambridge, MA on May 22-23, 2014 by GTC.
Dr Wishart will discuss how biomarkers must be robustly identifiable and accurately quantifiable to be validated, qualified or approved for clinical applications. He will share his laboratory’s efforts to develop a variety of quantitative metabolomic platforms for robust metabolite identification and quantification. He will then show how these data and these platforms can be used to discover and develop a number of metabolite biomarkers for a wide variety of diseases. In particular, Dr. Wishart will highlight some recent successes in his laboratory in finding metabolite biomarkers that can be used to predict or diagnose conditions such as cancer cachexia, pre-eclampsia, heart failure, transplant rejection, osteoarthritis and chronic fatigue syndrome. He will also discuss some of the difficulties that many researchers
face when trying to move biomarkers from the bench to the clinic. Dr. Wishart will use a recent example of a metabolomics based colonic polyp screening test that his laboratory helped to develop to illustrate the challenges and opportunities. The presentation will highlight the importance of quantification in “omics” measurements, describe key measurement and validation criteria for biomarker assessment, describe a pathway to metabolite biomarker testing and clinical translation as well as provide useful examples of clinical biomarker development for metabolomics.
Dr. David Wishart is a Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta. He has helped pioneer the field of quantitative metabolomics. From 2006-2009, Dr. Wishart led the “Human Metabolome Project” (HMP), a multi-university, multi-investigator project that catalogued all of the known metabolites in human tissues and biofluids. Using advanced methods in NMR spectroscopy, mass spectrometry, multi-dimensional chromatography and machine learning Dr. Wishart and his colleagues identified or found evidence for more than 18500 endogenous metabolites. This information has been archived on a freely accessible web-resource called the Human Metabolome Database (HMDB). The methods and ideas developed for the HMP have helped lay the foundation for a number of clinical metabolomics projects currently being pursued in his lab. These include studies aimed at identifying metabolite biomarkers for cancer, heart failure, chronic fatigue syndrome, pre-eclampsia and transplant rejection. Dr. Wishart has published more than 50 papers in the field of metabolomics and currently directs the Metabolomics Innovation Centre (TMIC), Canada’s national metabolomics platform.
GTC’s Metabolomics Conference program will discuss metabolite identification, standardization and validation, computational approaches to assessing the metabolome, advances in metabolite markers for personalized medicine, technological advances, clinical assay development and much more!
This conference is also part of the 2014 Drug Discovery Summit, which consists of this conference and three other conferences:
1) Bioanalytical Sensors
2) GPCR Structure, Function and Drug Discovery
3) Single Cell Analysis
For more information, please visit www.gtcbio.com/metabolomics